Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 143

1.

Cause-specific mortality among HIV-infected individuals, by CD4(+) cell count at HAART initiation, compared with HIV-uninfected individuals.

Wada N, Jacobson LP, Cohen M, French A, Phair J, Muñoz A.

AIDS. 2014 Jan 14;28(2):257-65. doi: 10.1097/QAD.0000000000000078.

2.

Timing of HAART initiation and clinical outcomes in human immunodeficiency virus type 1 seroconverters.

Writing Committee for the CASCADE Collaboration.

Arch Intern Med. 2011 Sep 26;171(17):1560-9. doi: 10.1001/archinternmed.2011.401.

3.
4.

Increased mortality among publicly insured participants in the HIV Outpatient Study despite HAART treatment.

Palella FJ Jr, Baker RK, Buchacz K, Chmiel JS, Tedaldi EM, Novak RM, Durham MD, Brooks JT; HOPS Investigators.

AIDS. 2011 Sep 24;25(15):1865-76. doi: 10.1097/QAD.0b013e32834b3537.

PMID:
21811144
5.

When to initiate combined antiretroviral therapy to reduce mortality and AIDS-defining illness in HIV-infected persons in developed countries: an observational study.

HIV-CAUSAL Collaboration, Cain LE, Logan R, Robins JM, Sterne JA, Sabin C, Bansi L, Justice A, Goulet J, van Sighem A, de Wolf F, Bucher HC, von Wyl V, Esteve A, Casabona J, del Amo J, Moreno S, Seng R, Meyer L, Perez-Hoyos S, Muga R, Lodi S, Lanoy E, Costagliola D, Hernan MA.

Ann Intern Med. 2011 Apr 19;154(8):509-15. doi: 10.7326/0003-4819-154-8-201104190-00001.

6.

The impact of kidney function at highly active antiretroviral therapy initiation on mortality in HIV-infected women.

Estrella MM, Parekh RS, Abraham A, Astor BC, Szczech LA, Anastos K, Dehovitz JA, Merenstein DJ, Pearce CL, Tien PC, Cohen MH, Gange SJ.

J Acquir Immune Defic Syndr. 2010 Oct;55(2):217-20. doi: 10.1097/QAI.0b013e3181e674f4.

7.

Mortality in an urban cohort of HIV-infected and at-risk drug users in the era of highly active antiretroviral therapy.

Kohli R, Lo Y, Howard AA, Buono D, Floris-Moore M, Klein RS, Schoenbaum EE.

Clin Infect Dis. 2005 Sep 15;41(6):864-72. Epub 2005 Aug 16.

PMID:
16107987
8.

The prognostic importance of changes in CD4+ cell count and HIV-1 RNA level in women after initiating highly active antiretroviral therapy.

Anastos K, Barrón Y, Cohen MH, Greenblatt RM, Minkoff H, Levine A, Young M, Gange SJ.

Ann Intern Med. 2004 Feb 17;140(4):256-64.

PMID:
14970148
9.

Mortality in the highly active antiretroviral therapy era: changing causes of death and disease in the HIV outpatient study.

Palella FJ Jr, Baker RK, Moorman AC, Chmiel JS, Wood KC, Brooks JT, Holmberg SD; HIV Outpatient Study Investigators.

J Acquir Immune Defic Syndr. 2006 Sep;43(1):27-34.

PMID:
16878047
10.
11.

Evaluation of the effectiveness of highly active antiretroviral therapy in persons with human immunodeficiency virus using biomarker-based equivalence of disease progression.

Jacobson LP, Li R, Phair J, Margolick JB, Rinaldo CR, Detels R, Muñoz A.

Am J Epidemiol. 2002 Apr 15;155(8):760-70.

PMID:
11943695
12.

Hepatitis B and long-term HIV outcomes in coinfected HAART recipients.

Hoffmann CJ, Seaberg EC, Young S, Witt MD, D'Acunto K, Phair J, Thio CL.

AIDS. 2009 Sep 10;23(14):1881-9. doi: 10.1097/QAD.0b013e32832e463a.

13.

Early mortality and cause of deaths in patients using HAART in Brazil and the United States.

Grinsztejn B, Veloso VG, Friedman RK, Moreira RI, Luz PM, Campos DP, Pilotto JH, Cardoso SW, Keruly JC, Moore RD.

AIDS. 2009 Oct 23;23(16):2107-14. doi: 10.1097/QAD.0b013e32832ec494.

14.

Hepatitis C and progression of HIV disease.

Sulkowski MS, Moore RD, Mehta SH, Chaisson RE, Thomas DL.

JAMA. 2002 Jul 10;288(2):199-206.

PMID:
12095384
15.

Pre-AIDS mortality in the Edinburgh City Hospital HIV cohort.

Seaman SR, Brettle RP, Gore SM.

Stat Med. 1997 Nov 15;16(21):2459-74.

PMID:
9364654
16.

The impact of HAART on the respiratory complications of HIV infection: longitudinal trends in the MACS and WIHS cohorts.

Gingo MR, Balasubramani GK, Kingsley L, Rinaldo CR Jr, Alden CB, Detels R, Greenblatt RM, Hessol NA, Holman S, Huang L, Kleerup EC, Phair J, Sutton SH, Seaberg EC, Margolick JB, Wisniewski SR, Morris A.

PLoS One. 2013;8(3):e58812. doi: 10.1371/journal.pone.0058812. Epub 2013 Mar 12.

17.

All-cause mortality in hospitalized HIV-infected patients at an acute tertiary care hospital with a comprehensive outpatient HIV care program in New York City in the era of highly active antiretroviral therapy (HAART).

Kim JH, Psevdos G Jr, Gonzalez E, Singh S, Kilayko MC, Sharp V.

Infection. 2013 Apr;41(2):545-51. doi: 10.1007/s15010-012-0386-7. Epub 2012 Dec 21.

PMID:
23264096
18.

Low CD4+ T-cell count as a major atherosclerosis risk factor in HIV-infected women and men.

Kaplan RC, Kingsley LA, Gange SJ, Benning L, Jacobson LP, Lazar J, Anastos K, Tien PC, Sharrett AR, Hodis HN.

AIDS. 2008 Aug 20;22(13):1615-24. doi: 10.1097/QAD.0b013e328300581d.

19.

Mortality in members of HIV-1 serodiscordant couples in Africa and implications for antiretroviral therapy initiation: results of analyses from a multicenter randomized trial.

de Bruyn G, Magaret A, Baeten JM, Lingappa JR, Ndase P, Celum C, Wald A; Partners in Prevention HSV/HIV Transmission Study Team.

BMC Infect Dis. 2012 Oct 30;12:277. doi: 10.1186/1471-2334-12-277.

20.

Predictors of mortality among HIV-infected women in Kigali, Rwanda.

Lindan CP, Allen S, Serufilira A, Lifson AR, Van de Perre P, Chen-Rundle A, Batungwanayo J, Nsengumuremyi F, Bogaerts J, Hulley S.

Ann Intern Med. 1992 Feb 15;116(4):320-8.

PMID:
1733389

Supplemental Content

Support Center